According to GuruFocus'Â All-In-One screener, the following are the highest-performing stocks in Paul Tudor Jones (Trades, Portfolio)’ portfolio during the first quarter of 2015.
Synergy Pharmaceuticals Inc. (SGYP)
He bought 11,517 shares of SGYP in Q1 2015 and since then, the stock has risen by 98.40%.
SGYP has a market cap of $913.42 million and an enterprise value of $934.79 million. It is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. Its product candidate is plecanatide, a guanylate cyclase C, or GC-C, receptor agonist, to treat GI disorders, primarily chronic idiopathic constipation, or CIC, and constipation-predominant- irritable bowel syndrome, or IBS-C. CIC and IBS-C are functional gastrointestinal disorders that affect millions of people worldwide.
The price of the stock has dropped by 25% during the last 5 years, but has risen by 185% since the beginning of the year and 128% during the last 12 months. The stock is now -10.05% from its 52-week high and +272.65% from its 52-week low.
The company has a profitability and growth ratio of 3/10 with deep negative returns (ROE -591%, ROA -92%).
John Paulson (Trades, Portfolio) is the main guru holding SGYP with 2,095,600 shares, or 2.09% of shares outstanding and 0.05% of total assets of his portfolio. Paul Tudor Jones (Trades, Portfolio) holds a very easy stake with about 0.01% of outstanding shares.
Agenus Inc. (AGEN)
In Q1 2015, he increased his stake in the company by 91.77% and now he holds 29,718 shares. Since then, the stock has risen by 79.30%.
AGEN has a market cap of $655.52 million and an enterprise value of $587.72 million. The Company, along with its subsidiaries, is a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators, heat shock protein vaccines and adjuvants. It is focused on immunotherapeutic products based on core platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. Its core technology portfolio consists of Heat Shock Protein Platform, and Saponin Platform.
The price of the stock has risen by 86% during the last 5 years; +130% since the beginning of the year and 181% during the last 12 months. The stock is now -9.74% from its 52-week high and +258.20% from its 52-week low.
The company has a profitability and growth rating of 2/10 with negative returns (ROE -127.15%, ROA -62.08%) that are ranked lower than 76% of its competitors.
Robert Bruce (Trades, Portfolio) is the main guru holding AGEN with 233,515 shares, or 0.33% of shares outstanding or 0.33% of total assets of his portfolio.
Alder BioPharmaceuticals Inc. (ALDR)
He also bought 8,816 shares of Alder BioPharmaceuticals and since then, the stock has risen by 73.10%.
ALDR has a market cap of $1.89 billion and an enterprise value of $1.66 billion. The Company is a clinical-stage bio-pharmaceutical company. The Company discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. It has developed a proprietary antibody platform designed to select antibodies that have the potential to maximize efficacy as well as speed of onset and durability of therapeutic response.
The price of the stock has risen by 397% during the last 5 years; +73% since the beginning of the year and 215% during the last 12 months. The stock is now -9.18% from its 52-week high and +373.95% from its 52-week low.
The company has a profitability and growth rating of 1/10 with almost null returns (ROE -0.71%, ROA -0.36%) that are ranked higher than 74% of its competitors.
Steven Cohen (Trades, Portfolio) is the main guru holding ALDR with 419,233 shares, or 1.10% of shares outstanding or 0.08% of total assets of his portfolio. Paul Tudor Jones (Trades, Portfolio) holds 0.02% of outstanding shares of the company.
EarthLink Holdings Corp. (ELNK)
He increased his stake in ELNK by 29.19% to 57,575 shares. Since then, the stock has risen by 68%.
ELNK has a market cap of $770.07 million and an enterprise value of $1.25 billion. The Company together with its subsidiaries provides Communication and IT services, empowering businesses with a fully-managed, end-to-end communications, IT and virtualization portfolio including cloud computing, IT security, colocation, enterprise-class hosted applications, secure network connectivity and IT support services.
The price of the stock has declined by 10% during the last 5 years (but has risen by 69% since the beginning of the year and 100% during the last 12 months) and is now -1.24% from its 52-week high and +157.12% from its 52-week low.
The company has a profitability and growth rating of 5/10 with negative returns (ROE -60%, ROA -6%) that are ranked higher/lower than 81% of its competitors.
Jim Simons (Trades, Portfolio) is the main guru holding ELNK with 4,473,000 shares, or 4.34% of shares outstanding or 0.04% of total assets of his portfolio. Chuck Royce (Trades, Portfolio) is the second main holder with 4.09% of outstanding shares of the company followed by Mario Gabelli (Trades, Portfolio) with 1.29%. Paul Tudor Jones (Trades, Portfolio) holds an easy stake of 0.06% of ELNK’s outstanding shares.
Imperva Inc (IMPV)
He increased his stake in IMPV by 350.06% to 56,870 shares. Since then, the stock has risen by 59.90%.
IMPV has a market cap of $2.11 billion and an enterprise value of $1.86 billion. The Company develops and sells data security solutions focused on providing visibility and control needed to neutralize attacks, theft and fraud from inside and outside the organization, mitigate risk, and streamline compliance. The Company's products include SecureSphere platform for enterprise data centers and cloud-based security services and Skyfence.
The price of the stock has risen by 187% during the last 5 years; +42% since the beginning of the year and 208% during the last 12 months. The stock is now -2.62% from its 52-week high and +215.66% from its 52-week low.
The company has a profitability and growth rating of 4/10 with very negative returns (ROE -50.81%, ROA -26.68%) that are ranked lower than 86% of its competitors.
John Burbank (Trades, Portfolio) is the main guru holding IMPV with 123,988 shares, or 0.41% of shares outstanding or 0.14% of total assets of his portfolio. Jim Simons (Trades, Portfolio) holds 0.39% of shares outstanding and Paul Tudor Jones (Trades, Portfolio) holds just 0.19%.
Sportsman’s Warehouse Holdings Inc (SPWH)
He bought 10,709 shares of SPWH. Since then, the stock has risen by 56%.
SPWH has a market cap of $526.31 million and an enterprise value of $745.41 million. The Company is an outdoor sporting goods retailer providing a one-stop shopping experience that equips its customers with the right hunting, shooting, fishing and camping gear to maximize their enjoyment of the outdoors.
The price of the stock has risen by 29% during the last 5 years; +70% since the beginning of the year and 75% during the last 12 months. The stock is now -1.67% from its 52-week high and +133.24% from its 52-week low.
The company has a profitability and growth rating of 4/10 with positive returns (ROA 5.42%) that is ranked higher than 70% of its competitors.
Jim Simons (Trades, Portfolio) is the main holder of the company with 0.34% of outstanding shares and Paul Tudor Jones (Trades, Portfolio) is the second, with 0.03%.
Summary :
| Ticker | Price growth since buy/increase | 5-year performance |
| SPWH | 56% | 29% |
| IMPV | 59.90% | 187% |
| ELNK | 68% | -10% |
| ALDR | 73.10% | 397% |
| AGEN | 79.30% | 86% |
| SGYP | 98.40% | -25% |
